Chuan Shih

National Health Research Institutes — Taiwan

Chemistry · Physical Sciences

41h-index4.3kcitations121works2.72yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Synthesis and biological activity(15), Cancer Mechanisms and Therapy(14), Melanoma and MAPK Pathways(12), Cancer therapeutics and mechanisms(12), Biochemical and Molecular Research(12)

Publications121 total

Advancing precision therapy for colorectal cancer: Developing clinical indications for multi-target kinase inhibitor BPR1J481 using patient-derived xenograft models
Pharmacological Research·2024· 3 citedOpen Access
DBPR116, a Prodrug of BPRMU191, in Combination with Naltrexone as a Safer Opioid Analgesic Than Morphine via Peripheral Administration
Journal of Medicinal Chemistry·2024· 2 cited
Discovery of a mu-opioid receptor modulator that in combination with morphinan antagonists induces analgesia
Cell chemical biology·2024· 3 cited
Supplementary Figure 2 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
2023Open Access
Supplementary Figure 2 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
2023Open Access
Data from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
2023Open Access
Data from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
2023Open Access
Supplementary Methods, Table 1 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
2023Open Access
Supplementary Figure 1 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
2023Open Access
Supplementary Figure 1 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
2023Open Access
Supplementary Methods, Table 1 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
2023Open Access
Benzo[b]thiophene-2-carboxamides as novel opioid receptor agonists with potent analgesic effect and reduced constipation
European Journal of Medicinal Chemistry·2022· 8 citedOpen Access
Selective and antagonist-dependent µ-opioid receptor activation by the combination of 2-{[2-(6-chloro-3,4-dihydro-1(2H)-quinolinyl)-2-oxoethyl]sulfanyl}-5-phenyl-4,6-(1H,5H)-pyrimidinedione and naloxone/naltrexone
Bioorganic Chemistry·2022· 6 cited
Discovery and development of a novel N-(3-bromophenyl)-{[(phenylcarbamoyl)amino]methyl}-N-hydroxythiophene-2-carboximidamide indoleamine 2,3-dioxygenase inhibitor using knowledge-based drug design
European Journal of Medicinal Chemistry·2021· 2 citedOpen Access
Discovery of BPR1R024, an Orally Active and Selective CSF1R Inhibitor that Exhibits Antitumor and Immunomodulatory Activity in a Murine Colon Tumor Model
Journal of Medicinal Chemistry·2021· 32 citedOpen Access
Discovery and Synthesis of a Pyrimidine-Based Aurora Kinase Inhibitor to Reduce Levels of MYC Oncoproteins
Journal of Medicinal Chemistry·2021· 19 citedOpen Access
Comparative study between deep learning and QSAR classifications for TNBC inhibitors and novel GPCR agonist discovery
Scientific Reports·2020· 100 citedOpen Access
Abstract 1937: BPR6K609: An Aurora kinase inhibitor targeting small cell lung cancer with MYC amplification
Cancer Research·2020
Correction to Unique Sulfur–Aromatic Interactions Contribute to the Binding of Potent Imidazothiazole Indoleamine 2,3-Dioxygenase Inhibitors
Journal of Medicinal Chemistry·2020
Unique Sulfur–Aromatic Interactions Contribute to the Binding of Potent Imidazothiazole Indoleamine 2,3-Dioxygenase Inhibitors
Journal of Medicinal Chemistry·2020· 39 cited
page 1 of 7Next →

Frequent Co-authors

Richard M. Schultz(13), Eileen L. Considine(9), Robert M. Campbell(8), Beverly A. Teicher(8), Harold B. Brooks(7), Guoxin Zhu(7), Margaret M. Faul(7), Shau‐Hua Ueng(6), Jen‐Shin Song(6), Su‐Ying Wu(6), Alfonso de Dios(6), Jack Dempsey(6), Charles D. Spencer(6), Scott A. Watkins(6), Ming‐Shiu Hung(5), Mine-Hsine Wu(5), Bryan D. Anderson(5), Tiechao Li(5), Lynn S. Gossett(5), Xun Zhou(5)